13 Facts About CureVac

CureVac had approximately 240 employees in November 2015 and 375 in May 2018.

At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine.

In mid-2021 it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval.

Also in 2013, CureVac announced the fourth in a series of partnerships with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.

In March 2014, CureVac won a €2 million prize awarded by the European Commission to stimulate new vaccine technologies.

Related searches

Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.

That same month, CureVac announced it would open a United States hub in Boston, Massachusetts.

In July 2020, Tesla, Inc CEO Elon Musk announced via Tweet that Tesla and CureVac had reached an agreement to produce portable "RNA microfactories" based on this technology to manufacture CureVac's COVID-19 vaccine candidate.

CureVac had stated that the bioprinters would be able to produce “more than a hundred thousand doses” within approximately two weeks.

On 14 August 2020, CureVac began public trading on the NASDAQ exchange under the ticker symbol, CVAC, raising in its initial public offering.

In January 2021, CureVac announced a clinical development collaboration for its COVID-19 vaccine, named CVnCoV, with the multinational pharmaceutical company Bayer.

On 12 February 2021, CureVac announced the initiation of a rolling submission with the European Medicines Agency for their vaccine candidate, a time-optimized process for the review of all data necessary for potential market authorization.

Beyond CVnCoV, CureVac has partnered with GlaxoSmithKline to develop a new generation of mRNA-based COVID-19 vaccines.